Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study has been completed.
Study NCT00669617   Information provided by Novartis
First Received: April 28, 2008   Last Updated: September 1, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiration Disorders
More general conditions related to this trial
Respiratory Tract Diseases
Interventions listed in this trial
Indacaterol 150 µg
Indacaterol 300 µg
Salmeterol/fluticasone (50/500 μg)
Salbutamol 200 µg
Placebo
Additional drug interventions recognized in this trial
Albuterol
Fluticasone
Salmeterol
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-Agonists
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services